Jakob Christian, Sterz Jan, Zavrski Ivana, Heider Ulrike, Kleeberg Lorenz, Fleissner Claudia, Kaiser Martin, Sezer Orhan
Department of Haematology and Oncology, Charité, Universitätsmedizin Berlin, Schumannstr. 20, D-10117 Berlin, Germany.
Eur J Cancer. 2006 Jul;42(11):1581-90. doi: 10.1016/j.ejca.2006.02.017. Epub 2006 Jun 23.
Multiple myeloma (MM) was the first haematological malignancy in which a prognostic relevance of bone marrow microvessel density (MVD) was shown. Myeloma-induced angiogenesis involves either the direct production of angiogenic molecules by myeloma cells or their induction in bone marrow stromal cells or endothelial cells (EC). Recent data demonstrate an increased angiogenic potential and a paracrine stimulatory effect of bone marrow EC on plasma cells (PC) in MM. Soluble angiogenic factors are elevated in bone marrow (BM) and in peripheral blood samples from myeloma patients. Furthermore, correlation with disease stage and prognosis was shown for serum levels of the angiogenic factors basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). In this review we summarize recent data which give strong evidence for an increased angiogenic activity in bone marrow microenvironment and support the hypothesis that angiogenesis is not only an epiphenomenon of tumour growth but may also promote PC growth in MM.
多发性骨髓瘤（MM）是首个显示骨髓微血管密度（MVD）具有预后相关性的血液系统恶性肿瘤。骨髓瘤诱导的血管生成涉及骨髓瘤细胞直接产生血管生成分子，或在骨髓基质细胞或内皮细胞（EC）中诱导产生血管生成分子。最近的数据表明，MM中骨髓EC的血管生成潜力增加，且对浆细胞（PC）具有旁分泌刺激作用。骨髓瘤患者的骨髓（BM）和外周血样本中可溶性血管生成因子水平升高。此外，血管生成因子碱性成纤维细胞生长因子（bFGF）、肝细胞生长因子（HGF）和血管内皮生长因子（VEGF）的血清水平与疾病分期和预后相关。在本综述中，我们总结了最近的数据，这些数据有力地证明了骨髓微环境中血管生成活性增加，并支持以下假说：血管生成不仅是肿瘤生长的一种附带现象，还可能促进MM中PC的生长。
